Kura Oncology Enters Material Definitive Agreement
Ticker: KURA · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $183,693, $2,399,031, $6,161,024 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation
Related Tickers: KURA
TL;DR
Kura Oncology just signed a big deal that means they owe money.
AI Summary
On January 13, 2025, Kura Oncology, Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company. The specific details of this agreement and the resulting obligation are not disclosed in this filing.
Why It Matters
This filing indicates Kura Oncology has entered into a significant agreement that creates a financial obligation, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce financial risks and operational changes that warrant closer monitoring.
Key Players & Entities
- Kura Oncology, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-37620 (company_id) — SEC File Number
- 61-1547851 (company_id) — IRS Employer Identification No.
- 12730 High Bluff Drive, Suite 400, San Diego, CA 92130 (address) — Principal Executive Offices
- (858) 500-8800 (phone_number) — Registrant's Telephone Number
FAQ
What is the nature of the material definitive agreement entered into by Kura Oncology?
The filing does not specify the nature of the material definitive agreement.
When did Kura Oncology enter into this material definitive agreement?
The earliest event reported is January 13, 2025.
What type of financial obligation did Kura Oncology create?
The filing states it is a direct financial obligation or an obligation under an off-balance sheet arrangement, but does not provide specifics.
Where is Kura Oncology's principal executive office located?
Kura Oncology's principal executive office is located at 12730 High Bluff Drive, Suite 400, San Diego, CA 92130.
What is Kura Oncology's SEC file number?
Kura Oncology's SEC file number is 001-37620.
Filing Stats: 809 words · 3 min read · ~3 pages · Grade level 12.2 · Accepted 2025-01-14 16:36:23
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se
- $183,693 — y under the Lease will be approximately $183,693 per month for the first year of the Lea
- $2,399,031 — ement in the total amount not to exceed $2,399,031 to be applied as a credit against the r
- $6,161,024 — nt allowance in an amount not to exceed $6,161,024, subject to certain conditions. In the
Filing Documents
- d875953d8k.htm (8-K) — 24KB
- 0001193125-25-006197.txt ( ) — 144KB
- kura-20250113.xsd (EX-101.SCH) — 3KB
- kura-20250113_lab.xml (EX-101.LAB) — 18KB
- kura-20250113_pre.xml (EX-101.PRE) — 11KB
- d875953d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KURA ONCOLOGY, INC. Date: January 14, 2025 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer